| Fall 2002 CARES Foundation, Inc. | |
| |
| Back to Fall 2002 Index | |
|
CAH Study at National Institutes of Health Bethesda, Maryland
|
|
Dr. Deborah Merke |
| We are currently recruiting children with classic 21-hydroxylase deficiency with a bone age between 2- 13 years (boys) or 2- 11 years (girls). Children will be enrolled in the study at the Warren Grant Magnuson Clinical Center of the National Institutes of Health in Bethesda, Maryland.
The conventional treatment of classical congenital adrenal hyperplasia (CAH) involves daily administration of hydrocortisone and fludrocortisone. One of the challenges in treating patients with CAH is finding the best dose of hydrocortisone. Treatment with too low a dose will fail to suppress the androgens optimally; treatment with too high a dose will cause weight gain, slow growth rate, and other features of hydrocortisone excess. This probably explains the finding that (treated) CAH patients average four inches shorter than would be expected based upon their parents' heights. To test the hypothesis that the regimen of flutamide (an antiandrogen), testolactone (an inhibitor of androgen-to -estrogen conversion), and reduced hydrocortisone can normalize the growth and adult stature of children with CAH, and avoid the complications of supraphysiologic glucocorticoid dosage, children with CAH will be randomized to receive either the above regimen or conventional treatment. For more information, contact: Dr. Deborah Merke or Meg Keil, NP at (301) 435-3391, fax: (301)-402-5618. |
||||
| ||||
 | ||||
| © 2002 CARES Foundation, Inc. All rights reserved. Republication or redistribution of CARES content, including by framing or similar means, is prohibited without the prior written consent of CARES. | ||||